. 2022 May 2;5(5):278–298. doi: 10.1021/acsptsci.2c00033

Table 2. Some Examples of Co-encapsulation of Anticancer Agents in PNCs.

co-encapsulated anticancer agents	composition of PNC	size (nm)	surface properties	target tissue	status	ref
DOX, epoxomicin	PLGA	162.1–179.6	unconjugated	breast cancer	in vitro	(139)
PTX, lapatinib	PLA–PEG	100 (filomicelles), 20 (spherical micelles)	PEG₅₀₀₀ylated	breast cancer	in vitro	(140)
gefitinib, vorinostat	hyaluronan, PBLG	30	unconjugated	lung cancer	in vitro, in vivo	(141)
DOX, anti-BCL-2 siRNA	PEG–PLL–PAsp(DIP) (pH-sensitive)	60	PEGylated	hepatic carcinoma	in vitro, in vivo	(142)
DOX, DTX	mPEG–PCL (redox-sensitive)	223.7	mPEG₂₀₀₀ylated	breast cancer	in vitro	(143)
DOX, IFN-γ	PLGA, Pluronic F127	100	PEO-conjugated	melanoma	in vitro, in vivo	(144)
DOX, recombinant human IL-2	trimethyl chitosan (pH-sensitive)	200	folate-conjugated	hepatic carcinoma	in vitro, in vivo	(145)
DOX, miRNA-34a (tumor suppressor micro-RNA)	PEG₂₀₀₀-CLV (MMP2-sensitive)	15	PEG₂₀₀₀ylated	fibrosarcoma	in vitro	(146)
DOX, P-gp siRNA	FA/m-PEG-b-P(LG-Hyd)-b-PDMAPMA	196.8	folate-conjugated	breast cancer	in vitro	(147)
TMX, quercetin	PLGA	185.3 ± 1.20	unconjugated	breast cancer, colon cancer	in vitro, in vivo	(148)